A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients

NCT ID: NCT02119260

Last Updated: 2018-09-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-09
• Study Completion Date: 2016-12-25

Brief Summary

This study is the first administration of GSK2798745 in humans. This will be a sponsor un-blinded, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2798745, given as single and repeat oral doses to healthy subjects and stable heart failure (HF) subjects. Approximately 28 healthy subjects will be enrolled in the study cohorts (Cohort 1-3) involving single and repeat dose escalations of GSK2798745, while up to 24 stable heart failure subjects will be enrolled in Cohort 4 involving single and repeat dose administration of GSK2798745, with the dose selected based on data from healthy subject cohorts. This would be followed by enrollment of up to 8 subjects with heart failure in Cohort 5 involving repeat dose administration of GSK2798745. The study duration, including screening and follow-up, is not expected to exceed 17 weeks for subjects in the study (in any cohort).

Conditions

Oedema, Pulmonary

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Cohort 1

Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).

Group Type: EXPERIMENTAL

GSK2798745 solution

Intervention Type: DRUG

Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol

GSK2798745 suspension

Intervention Type: DRUG

Aqueous suspension of GSK2798745 (\>=0.5 mg)

Placebo solution

Intervention Type: DRUG

Clear, colourless solution of aqueous citrate buffer with 4% captisol

Placebo suspension

Intervention Type: DRUG

Visually matching aqueous suspension of hypromellose acetate succinate powder

Cohort 2

Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.

Group Type: EXPERIMENTAL

GSK2798745 solution

Intervention Type: DRUG

Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol

GSK2798745 suspension

Intervention Type: DRUG

Aqueous suspension of GSK2798745 (\>=0.5 mg)

GSK2798745 capsule

Intervention Type: DRUG

White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)

Cohort 3

Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.

Group Type: EXPERIMENTAL

GSK2798745 solution

Intervention Type: DRUG

Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol

GSK2798745 suspension

Intervention Type: DRUG

Aqueous suspension of GSK2798745 (\>=0.5 mg)

GSK2798745 capsule

Intervention Type: DRUG

White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)

Placebo solution

Intervention Type: DRUG

Clear, colourless solution of aqueous citrate buffer with 4% captisol

Placebo suspension

Intervention Type: DRUG

Visually matching aqueous suspension of hypromellose acetate succinate powder

Placebo capsule

Intervention Type: DRUG

Matching white opaque placebo blend filled capsule

Cohort 4

Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.

Group Type: EXPERIMENTAL

GSK2798745 capsule

Intervention Type: DRUG

White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)

Placebo capsule

Intervention Type: DRUG

Matching white opaque placebo blend filled capsule

Cohort 5

Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.

Group Type: EXPERIMENTAL

GSK2798745 capsule

Intervention Type: DRUG

White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)

Placebo capsule

Intervention Type: DRUG

Matching white opaque placebo blend filled capsule

Interventions

GSK2798745 solution

Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol

Intervention Type: DRUG

GSK2798745 suspension

Aqueous suspension of GSK2798745 (\>=0.5 mg)

Intervention Type: DRUG

GSK2798745 capsule

White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)

Intervention Type: DRUG

Placebo solution

Clear, colourless solution of aqueous citrate buffer with 4% captisol

Intervention Type: DRUG

Placebo suspension

Visually matching aqueous suspension of hypromellose acetate succinate powder

Intervention Type: DRUG

Placebo capsule

Matching white opaque placebo blend filled capsule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

For Healthy Subject Cohorts (1-3):

• Male or female 18-75 years of age inclusive, at the time of signing the informed consent.

Exclusion Criteria

• Body weight >=50 kilogram (kg) and Body Mass Index (BMI) within the range 18-32 kilogram/ square meter (kg/m^2) (inclusive).
• A female subject is eligible to participate if she is of Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, "documented" refers to the outcome of the Investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-International Units per milliliter (mIU/mL) and estradiol <40 picogram/millilitre (pg/mL) [<147 picomoles/liter (pmol/L)] is confirmatory.
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 2 weeks post last dose.
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• Alanine transaminase (ALT), alkaline phosphatase and bilirubin <= 1.5x Upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
• Based on averaged QTc values of triplicate ECGs obtained over a brief recording period: QTc <450 milliseconds (msec); or QTc <480 msec in subjects with Bundle Branch Block.

For Heart Failure Subjects (Cohorts 4 and 5):

• Established diagnosis of mild or moderate heart failure of any aetiology with symptoms defined as corresponding to the New York Heart Association (NYHA) Class II or III on stable heart failure therapy for at least 1 month and was not hospitalized for HF for the last three months.
• Male or female 18 years or older, age inclusive, at the time of signing the informed consent.
• ALT, alkaline phosphatase and bilirubin <=1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
• Based on averaged QTc values of triplicate ECGs obtained over a brief recording period: QTc <450msec; or QTc <480msec in subjects with Bundle Branch Block.
• Female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy for this definition, "documented" refers to the outcome of the Investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records; or postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) >40mIU/mL and estradiol <40pg/mL (<147pmol/L) is confirmatory.
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until 2 weeks post-last dose.
• Body weight >=50kg and BMI within the range 18-40kg/m^2 (inclusive).
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 6 months.
• History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 gram (g) of alcohol: a half-pint (approximately 240mL) of beer, 1 glass (125mL) of wine or 1 (25mL) measure of spirits.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator and/or GSK Medical Monitor, contraindicates their participation.
• History of seizure disorder and or stroke within the last 5 years.
• Active ulcer disease or gastrointestinal (GI) bleeding.
• Current smokers (Cohorts 1-4 only).
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
• A positive pre-study drug/alcohol screen.
• A positive test for human immunodeficiency virus (HIV) antibody.
• A screening cardiac Troponin (cTn) level >ULN.
• Baseline presence of severe aortic stenosis.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• Left ventricular ejection fraction <50 percent - (Healthy subjects only).
• Subject who, in the Investigator/designee's judgement, poses a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behaviour and/or any evidence of suicidal ideation on any questionnaires e.g., Type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) in the last 5 years.

For Heart Failure Subjects (Cohort 4):

• History of known primary pulmonary disease requiring current medication or other therapy.
• Orthopnoea of sufficient severity to preclude supine scanning as determined at screening.
• Uncontrolled hypertension (resting systolic blood pressure [BP] > 160 millimeters of mercury [mmHg] or resting diastolic BP > 100 mmHg).
• Resting hypoxia while breathing room air (Peripheral capillary oxygen saturation [SpO2] <88 percent).
• Estimated creatinine clearance (Cockcroft-Gault) <40 mL/minute.
• Contraindication to magnetic resonance imaging (MRI) contrast agents.
• Contraindication for MRI scanning (as assessed by local MRI safety questionnaire), which includes but is not limited to: a. Intracranial aneurysm clips (except Sugita^®; trademark owned by Mizuho Ikakogyo Co.Ltd. Tokyo) or other metallic objects; b. Intra- orbital metal fragments that have not been removed; c. Pacemakers or other implanted cardiac rhythm management/monitoring devices and non-MR conditional heart valves; d. Inner ear implants; and e. History of claustrophobia.

For Heart Failure Subjects (Cohort 5):

• Uncontrolled hypertension (resting SBP >160 mmHg or reporting DBP >100 mmHg).
• Resting hypoxia while breathing room air (SpO2 <88 percent).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Cambridge, , United Kingdom

GSK Investigational Site

London, , United Kingdom

Countries

United Kingdom

References

Goyal N, Skrdla P, Schroyer R, Kumar S, Fernando D, Oughton A, Norton N, Sprecher DL, Cheriyan J. Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects. Am J Cardiovasc Drugs. 2019 Jun;19(3):335-342. doi: 10.1007/s40256-018-00320-6.

Reference Type: DERIVED

PMID: 30637626 (View on PubMed)

Other Identifiers

117387

Identifier Type: -

Identifier Source: org_study_id